Terapêutica

NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England Journal of MedicinePatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment...

BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

British Medical JournalTo estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital,...

THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

The LancetMany patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.

JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA NETWORK

The results do not support routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients with COVID-19 admitted to the ICU.

JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

JAMA NETWORKIn a meta-analysis of 4 peer-reviewed and published randomized clinical trials including 1060 patients with COVID-19 treated with convalescent plasma vs control, the risk ratio for mortality was 0.93 and after the addition of 6...

NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

The New England Journal of MedicineAs mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled...

BMJ - Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

British Medical JournalOf 4297 patients admitted to hospital with covid-19, 3627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin....

JAMA - Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

JAMA NETWORKMultisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy...

BMJ - Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

British Medical JournalThe coronavirus disease 2019 (covid-19) pandemic has led to profound worldwide health, economic, and social losses. As of October 2020, more than 40 million people have received a diagnosis of covid-19 and one million...

NEJM - Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

BMJ - Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

JAMA - Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

BMJ - Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

NEJM - Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

AMP - The Role of Pharmacovigilance in the COVID-19 Pandemic

THE LANCET - 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

NEJM - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

NEJM - Tocilizumab in Patients Hospitalized with Covid-19

NEJM - Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Categorias

Arquivo